{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:20:06Z","timestamp":1778941206203,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.clgc.2016.03.012","type":"journal-article","created":{"date-parts":[[2016,3,12]],"date-time":"2016-03-12T10:45:39Z","timestamp":1457779539000},"page":"e445-e448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Novel Use of Targeted Therapy via PARP-Inhibition in a Rare Form of Papillary Renal Cell Carcinoma: A Case Report and Literature Review"],"prefix":"10.1016","volume":"14","author":[{"given":"Daniel","family":"Olson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savita","family":"Bhalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ximing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda","family":"Martone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy M.","family":"Kuzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2016.03.012_bib1","first-page":"10","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2016.03.012_bib2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrurol.2010.47","article-title":"The genetic basis of kidney cancer: a metabolic disease","volume":"7","author":"Linehan","year":"2010","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.clgc.2016.03.012_bib3","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/00000478-199706000-00001","article-title":"Papillary (chromophil) renal cell\u00a0carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases","volume":"21","author":"Amin","year":"1997","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clgc.2016.03.012_bib4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G","article-title":"The Heidelberg classification of renal cell tumours","volume":"183","author":"Kovacs","year":"1997","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.clgc.2016.03.012_bib5","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.eururo.2005.11.035","article-title":"2004 WHO classification of the renal tumors of the adults","volume":"49","author":"Lopez-Beltran","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2016.03.012_bib6","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1097\/01.pas.0000184821.09871.ec","article-title":"Adult papillary renal tumor with oncocytic cells: clinicopathologic, immunohistochemical, and cytogenetic features of 10 cases","volume":"29","author":"Lefevre","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clgc.2016.03.012_bib7","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrm2514","article-title":"Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer","volume":"9","author":"Lavin","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.clgc.2016.03.012_bib8","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/nrc2248","article-title":"The impact of a negligent G2\/M checkpoint on genomic instability and cancer induction","volume":"7","author":"Lobrich","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clgc.2016.03.012_bib9","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/258427a0","article-title":"Ataxia telangiectasia: a human mutation with abnormal radiation sensitivity","volume":"258","author":"Taylor","year":"1975","journal-title":"Nature"},{"key":"10.1016\/j.clgc.2016.03.012_bib10","doi-asserted-by":"crossref","first-page":"D805","DOI":"10.1093\/nar\/gku1075","article-title":"COSMIC: exploring the world's knowledge of somatic mutations in human cancer","volume":"43","author":"Forbes","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.clgc.2016.03.012_bib11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clgc.2016.03.012_bib12","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"10.1016\/j.clgc.2016.03.012_bib13","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1158\/1535-7163.MCT-09-0872","article-title":"ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors","volume":"9","author":"Williamson","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clgc.2016.03.012_bib14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5306\/wjco.v2.i2.73","article-title":"Exploiting the homologous recombination DNA repair network for targeted cancer therapy","volume":"2","author":"Peng","year":"2011","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.clgc.2016.03.012_bib15","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1182\/blood-2010-01-265769","article-title":"The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in\u00a0vitro and in\u00a0vivo","volume":"116","author":"Weston","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clgc.2016.03.012_bib16","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/emmm.201200229","article-title":"Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53","volume":"4","author":"Williamson","year":"2012","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.clgc.2016.03.012_bib17","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.2174\/092986712802002464","article-title":"Role of PARP inhibitors in cancer biology and therapy","volume":"19","author":"Davar","year":"2012","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.clgc.2016.03.012_bib18","first-page":"301","article-title":"The ups and downs of DNA repair biomarkers for PARP inhibitor therapies","volume":"1","author":"Wang","year":"2011","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.clgc.2016.03.012_bib19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrc2342","article-title":"DNA repair pathways as targets for cancer therapy","volume":"8","author":"Helleday","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clgc.2016.03.012_bib20","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.03.012_bib21","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.urology.2015.05.008","article-title":"Trends in metastatic kidney cancer survival from the cytokine to the targeted therapy era","volume":"86","author":"Macleod","year":"2015","journal-title":"Urology"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316300660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316300660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:26:44Z","timestamp":1761564404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767316300660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S1558767316300660"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2016.03.012","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Use of Targeted Therapy via PARP-Inhibition in a Rare Form of Papillary Renal Cell Carcinoma: A Case Report and Literature Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2016.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}